| 4.17 -0.02 (-0.48%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.49 | 1-year : | 5.98 |
| Resists | First : | 4.7 | Second : | 5.11 |
| Pivot price | 4.76 |
|||
| Supports | First : | 4.03 | Second : | 3.36 |
| MAs | MA(5) : | 4.61 |
MA(20) : | 4.75 |
| MA(100) : | 5.33 |
MA(250) : | 7.84 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 40.2 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 14.68 | Low : | 4.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAGE ] has closed below the lower bollinger band by 10.5%. Bollinger Bands are 35.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.26 - 4.29 | 4.29 - 4.31 |
| Low: | 3.98 - 4.01 | 4.01 - 4.03 |
| Close: | 4.13 - 4.18 | 4.18 - 4.21 |
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Sat, 09 May 2026
Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus? - Yahoo Finance
Sat, 09 May 2026
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results - Streetwise Reports
Fri, 08 May 2026
Niagen Bioscience Announces Participation in Upcoming Investor Conferences - Business Wire
Thu, 07 May 2026
Niagen Bioscience Earnings Call Highlights Growth Push - The Globe and Mail
Thu, 07 May 2026
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Sahm
Wed, 06 May 2026
Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 29.2 (%) |
| Held by Institutions | 41.3 (%) |
| Shares Short | 5,450 (K) |
| Shares Short P.Month | 5,580 (K) |
| EPS | 0.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.95 |
| Profit Margin | 13.4 % |
| Operating Margin | 6.2 % |
| Return on Assets (ttm) | 10.2 % |
| Return on Equity (ttm) | 28.3 % |
| Qtrly Rev. Growth | 16.2 % |
| Gross Profit (p.s.) | 1.04 |
| Sales Per Share | 1.62 |
| EBITDA (p.s.) | 0.18 |
| Qtrly Earnings Growth | -41.6 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | 20.85 |
| PEG Ratio | 0 |
| Price to Book value | 4.34 |
| Price to Sales | 2.56 |
| Price to Cash Flow | 24.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|